Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025. On November 10, Oppenheimer analyst Jay Olson reaffirmed his Outperform rating on Nektar The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback